The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A08 | Antiobesity preparations, excl. diet products | |
| 3 | A08A | Antiobesity preparations, excl. diet products | |
| 4 | A08AA | Centrally acting antiobesity products | |
| 5 | A08AA04 | Dexfenfluramine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 30 mg |
| Active Ingredient | Description | |
|---|---|---|
| Dexfenfluramine |
Dexfenfluramine is the d-enantiomer of fenfluramine (structurally similar to amphetamine) and acts as a serotonergic anorectic drug that reduces appetite by increasing the amount of extracellular serotonin in the brain. |
